TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value

Critical Reviews in Oncology/Hematology

Volumn 99, Issue , 2016, Pages 63-73

  Deben, Christophe ^a,b   Deschoolmeester, Vanessa ^a,b   Lardon, Filip ^a   Rolfo, Christian ^b   Pauwels, Patrick ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

MDM2; NSCLC; P53; Predictive; Prognosis

Indexed keywords

CISPLATIN; PROTEIN MDM2; PROTEIN P53; MDM2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

AMINO ACID SUBSTITUTION; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; MDM2 GENE; NON SMALL CELL LUNG CANCER; PREDICTIVE VALUE; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL CELL LUNG CANCER; TREATMENT INDICATION; TUMOR SUPPRESSOR GENE; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; GENOTYPE; LUNG NEOPLASMS; MUTATION; PROGNOSIS;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; GENOTYPE; HUMANS; LUNG NEOPLASMS; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84959540886     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.11.019     Document Type: Review

References (90)

1. Ahrendt S.A., Hu Y., Buta M., McDermott M.P., Benoit N., Yang S.C., et al. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. J. Natl. Cancer Inst. 2003, 95:961-970.
2. Amaral J.D., Xavier J.M., Steer C.J., Rodrigues C.M. The role of p53 in apoptosis. Discov. Med. 2010, 9:145-152.
3. Anon., 2015a. Non-small cell lung cancer survival rates by stage. Available: .
4. Anon., 2015. Pembrolizumab injection. Available: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm465650.htm (accessed 19.10.15.).
5. Boldrini L., Gisfredi S., Ursino S., Lucchi M., Greco G., Mussi A., et al. Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis. Cancer Invest. 2008, 26:168-172.
6. Boldrini L., Gisfredi S., Ursino S., Lucchi M., Greco G., Mussi A., et al. Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients. Oncol. Rep. 2008, 19:771-773.
7. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602.
8. Bond G.L., Hirshfield K.M., Kirchhoff T., Alexe G., Bond E.E., Robins H., et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 2006, 66:5104-5110.
9. Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. New Engl. J. Med. 2015.
10. Brahmer J., Reckamp K.L., Baas P., Crino L., Eberhardt W.E., Poddubskaya E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. New Engl. J. Med. 2015, 373:123-135.
11. Bykov V.J., Zache N., Stridh H., Westman J., Bergman J., Selivanova G., et al. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005, 24:3484-3491.
12. Campling B.G., el-Deiry W.S. Clinical implications of p53 mutations in lung cancer. Methods Mol. Med. 2003, 75:53-77.
13. Cancer Research UK, 2015. Lung cancer statistics. Available: (accessed 19.10.15.).
14. Candeias M.M., Malbert-Colas L., Powell D.J., Daskalogianni C., Maslon M.M., Naski N., et al. P53 mRNA controls p53 activity by managing Mdm2 functions. Nat. Cell Biol. 2008, 10:1098-1105.
15. Chene P. The role of tetramerization in p53 function. Oncogene 2001, 20:2611-2617.
16. Chien W.P., Wong R.H., Wu T.C., Cheng Y.W., Chen C.Y., Lee H. Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer. Ann. Surg. Oncol. 2009, 16:1918-1924.
17. Chien W.P., Wong R.H., Cheng Y.W., Chen C.Y., Lee H. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors. Ann. Surg. Oncol. 2010, 17:1194-1202.
18. Deben C., Wouters A., Op, de B., eeck K., van D., en B., ossche J., Jacobs J., Zwaenepoel K., et al. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer. Oncotarget 2015, 6:22666-22679.
19. Dela Cruz C.S., Tanoue L.T., Matthay R.A. Lung cancer: epidemiology, etiology, and prevention. Clin. Chest Med. 2011, 32:605-644.
20. Dickens M.P., Fitzgerald R., Fischer P.M. Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Semin. Cancer Biol. 2010, 20:10-18.
21. Dong J., Ren B., Hu Z., Chen J., Hu L., Dai J., et al. MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese. Mol. Carcinog. 2011, 50:433-438.
22. Dumont P., Leu J.I.J., Della P., ietra A.C., George D.L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 2003, 33:357-365.
23. Dworakowska D., Jassem E., Jassem J., Peters B., Dziadziuszko R., Zylicz M., et al. MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). Lung Cancer 2004, 43:285-295.
24. Gansmo L.B., Knappskog S., Romundstad P., Hveem K., Vatten L., Lonning P.E. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon. Int. J. Cancer 2014.
25. Garon E.B., Cao D., Alexandris E., John W.J., Yurasov S., Perol M. A randomized, double-blind, phase III study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design. Clin. Lung Cancer 2012, 13:505-509.
26. Gemignani F., Moreno V., Landi S., Moullan N., Chabrier A., Gutierrez-Enriquez S., et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004, 23:1954-1956.
27. Hai J., Sakashita S., Allo G., Ludkovski O., Ng C., Shepherd F.A., et al. Inhibiting MDM2-p53 Interaction suppresses tumor growth in patient-derived non-small cell lung cancer xenograft models. J. Thoracic Oncol. 2015, 10:1172-1180.
28. Han J.Y., Lee G.K., Jang D.H., Lee S.Y., Lee J.S. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008, 113:799-807.
29. He X.F., Su J., Zhang Y., Huang X., Liu Y., Ding D.P., et al. Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res. Treat. 2011, 130:517-529.
30. Heist R.S., Zhou W., Chirieac L.R., Cogan-Drew T., Liu G., Su L., et al. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J. Clin. Oncol. 2007, 25:2243-2247.
31. Higashiyama M., Doi O., Kodama K., Yokouchi H., Kasugai T., Ishiguro S., et al. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br. J. Cancer 1997, 75:1302-1308.
32. Higgins B., Glenn K., Walz A., Tovar C., Filipovic Z., Hussain S., et al. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Clinical cancer research: an official journal of the 2014, 20:3742-3752.
33. Hoe K.K., Verma C.S., Lane D.P. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat. Rev. Drug Discovery 2014, 13:217-236.
34. Hu Z., Li X., Qu X., He Y., Ring B.Z., Song E., et al. Intron 3 16bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis 2010, 31:643-647.
35. -2 interaction and activates p53 function in tumors. Nat. Med. 2004, 10:1321-1328.
36. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
37. Junker K., Wiethege T., Muller K.M., Thomas M. p53 tumour-suppressor gene in non-small-cell lung cancer with neoadjuvant therapy. J. Cancer Res. Clin. Oncol. 2000, 126:238-245.
38. Kandioler D., Stamatis G., Eberhardt W., Kappel S., Zochbauer-Muller S., Kuhrer I., et al. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. J. Thoracic Cardiovasc. Surg. 2008, 135:1036-1041.
39. Knappskog S., Bjornslett M., Myklebust L.M., Huijts P.E., Vreeswijk M.P., Edvardsen H., et al. The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell 2011, 19:273-282.
40. Komiya T., Thomas A., Khozin S., Rajan A., Wang Y., Giaccone G. Response to crizotinib in ROS1-rearranged non-small-cell lung cancer. J. Clin. Oncol. 2012, 30:3425-3426. author reply 6.
41. Kong Q., Li P., Tian Q., Ha M.W. Role of MDM2 T309G polymorphism in susceptibility and prognosis of nonsmall cell lung cancer: a meta-analysis. Genet. Test. Mol. Biomarkers 2014, 18:357-365.
42. Laudanski J., Niklinska W., Burzykowski T., Chyczewski L., Niklinski J. Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer. Eur. Respir. J. 2001, 17:660-666.
43. Li X., Dumont P., Della P., ietra A., Shetler C., Murphy M.E. The codon 47 polymorphism in p53 is functionally significant. J. Biol. Chem. 2005, 280:24245-24251.
44. Li G., Zhai X., Zhang Z., Chamberlain R.M., Spitz M.R., Wei Q. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 2006, 27:2028-2033.
45. Lind H., Zienolddiny S., Ekstrom P.O., Skaug V., Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int. J. Cancer 2006, 119:718-721.
46. Liu L., Wu C., Wang Y., Zhong R., Duan S., Wei S., et al. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J. Thoracic Oncol. 2011, 6:1793-1800.
47. Ma X., Rousseau V., Sun H., Lantuejoul S., Filipits M., Pirker R., et al. Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer. Mol. Oncol. 2014, 8:555-564.
48. Marchetti A., Buttitta F., Pellegrini S., Merlo G., Chella A., Angeletti C.A., et al. mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn. Mol. Pathol. B 1995, 4:93-97.
49. Matakidou A., Eisen T., Houlston R.S. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 2003, 18:377-385.
50. Matakidou A., El G., alta R., Webb E.L., Rudd M.F., Bridle H., Eisen T., et al. Lack of evidence that p53 Arg72Pro influences lung cancer prognosis: an analysis of survival in 619 female patients. Lung Cancer 2007, 57:207-212.
51. Meek D.W., Hupp T.R. The regulation of MDM2 by multisite phosphorylation-opportunities for molecular-based intervention to target tumours. Semin. Cancer Biol. 2010, 20:19-28.
52. Mitsudomi T., Hamajima N., Ogawa M., Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clinical cancer research: an official journal of the 2000, 6:4055-4063.
53. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010, 11:121-128.
54. Mogi A., Kuwano H. TP53 mutations in nonsmall cell lung cancer. J. Biomed. Biotechnol. 2011, 583929.
55. Mohell N., Alfredsson J., Fransson A., Uustalu M., Bystrom S., Gullbo J., et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis. 2015, 6:e1794.
56. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl. J. Med. 2009, 361:947-957.
57. Moll U.M., Petrenko O. The MDM2-p53 interaction. Mol. Cancer Res. 2003, 1:1001-1008.
58. Momand J., Jung D., Wilczynski S., Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998, 26:3453-3459.
59. Morgan M.A., Parsels L.A., Maybaum J., Lawrence T.S. Improving the efficacy of chemoradiation with targeted agents. Cancer Discovery 2014, 4:280-291.
60. Mori S., Ito G., Usami N., Yoshioka H., Ueda Y., Kodama Y., et al. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer 2004, 100:1673-1682.
61. Murakami I., Hiyama K., Ishioka S., Yamakido M., Kasagi F., Yokosaki Y. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients. Clinical cancer research: an official journal of the 2000, 6:526-530.
62. Ray-Coquard I., Blay J.Y., Italiano A., Le C., esne A., Penel N., Zhi J., et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012, 13:1133-1140.
63. Reck M., Kaiser R., Mellemgaard A., Douillard J.Y., Orlov S., Krzakowski M., et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014, 15:143-155.
64. Regina S., Valentin J.B., Lachot S., Lemarie E., Rollin J., Gruel Y. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN. Clin. Chem. 2009, 55:1834-1842.
65. Reles A., Wen W.H., Schmider A., Gee C., Runnebaum I.B., Kilian U., et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clinical cancer research: an official journal of the 2001, 7:2984-2997.
66. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13:239-246.
67. Ryan B.M., Calhoun K.M., Pine S.R., Bowman E.D., Robles A.I., Ambs S., et al. MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer. Int. J. Cancer 2012, 131:2710-2716.
68. Scoccianti C., Vesin A., Martel G., Olivier M., Brambilla E., Timsit J.F., et al. Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. Eur. Respir. J. 2012, 40:177-184.
69. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crino L., Ahn M.J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. New Engl. J. Med. 2013, 368:2385-2394.
70. Shaw A.T., Ou S.H., Bang Y.J., Camidge D.R., Solomon B.J., Salgia R., et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. New Engl. J. Med. 2014, 371:1963-1971.
71. Shiraishi K., Kohno T., Tanai C., Goto Y., Kuchiba A., Yamamoto S., et al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:4945-4952.
72. Sioris T., Husgafvel-Pursiainen K., Karjalainen A., Anttila S., Kannio A., Salo J.A., et al. Survival in operable non-small-cell lung cancer: role of p53 mutations, tobacco smoking and asbestos exposure. Int. J. Cancer 2000, 86:590-594.
73. Skaug V., Ryberg D., Kure E.H., Arab M.O., Stangeland L., Myking A.O., et al. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clinical cancer research: an official journal of the 2000, 6:1031-1037.
74. Solomon B.J., Mok T., Kim D.-W., Wu Y.-L., Nakagawa K., Mekhail T., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Engl. J. Med. 2014, 371:2167-2177.
75. Soria J.C., Mauguen A., Reck M., Sandler A.B., Saijo N., Johnson D.H., et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann. Oncol. 2013, 24:20-30.
76. Steels E., Paesmans M., Berghmans T., Branle F., Lemaitre F., Mascaux C., et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur. Respir. J. 2001, 18:705-719.
77. Syljuåsen R.G., Hasvold G., Hauge S., Helland Å. Targeting lung cancer through inhibition of checkpoint kinases. Front. Genet. 2015, 6.
78. Tovar C., Graves B., Packman K., Filipovic Z., Higgins B., Xia M., et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res. 2013, 73:2587-2597.
79. Tsao M.S., Aviel-Ronen S., Ding K., Lau D., Liu N., Sakurada A., et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J. Clin. Oncol. 2007, 25:5240-5247.
80. Vansteenkiste J., De Ruysscher D., Eberhardt W.E., Lim E., Senan S., Felip E., et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013, 24(Suppl. 6):vi89-vi98.
81. Vaseva A.V., Moll U.M. The mitochondrial p53 pathway. Biochim. Biophys. Acta 2009, 1787:414-420.
82. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
83. Viktorsson K., De P., etris L., Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem. Biophys. Res. Commun. 2005, 331:868-880.
84. Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994, 84:3148-3157.
85. Whibley C., Pharoah P.D., Hollstein M. p53 polymorphisms: cancer implications. Nat. Rev. Cancer 2009, 9:95-107.
86. Wilkening S., Bermejo J.L., Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 2007, 28:2262-2267.
87. Wu X., Zhao H., Amos C.I., Shete S., Makan N., Hong W.K., et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J. Natl. Cancer Inst. 2002, 94:681-690.
88. Zandi R., Selivanova G., Christensen C.L., Gerds T.A., Willumsen B.M., Poulsen H.S. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clinical cancer research: an official journal of the 2011, 17:2830-2841.
89. Zhuo W., Zhang L., Zhu B., Ling J., Chen Z. Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls. PLoS One 2012, 7:e41546.
90. Zilfou J.T., Lowe S.W. Tumor suppressive functions of p53. Cold Spring Harbor Perspect. Biol. 2009, 1:a001883.